{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=3", "query": { "intervention": "Placebo to risperidone", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 58, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+risperidone&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T19:28:52.443Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00567710", "title": "A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "BL - 1020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 360, "start_date": "2008-07", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2010-06-29", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 1, "location_summary": "Irving, Texas", "locations": [ { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567710" }, { "nct_id": "NCT02019329", "title": "A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "RO5545965", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 32, "start_date": "2014-01", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02019329" }, { "nct_id": "NCT01786239", "title": "Omega-3 Dietary Supplements in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia", "Schizophreniform Disorder", "Schizoaffective Disorder", "Bipolar Disorder", "Psychosis NOS" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Omega-3 capsules", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delbert Robinson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 50, "start_date": "2013-05", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 1, "location_summary": "Glen Oaks, New York", "locations": [ { "city": "Glen Oaks", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786239" }, { "nct_id": "NCT04624243", "title": "Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo to MK-8189", "type": "DRUG" }, { "name": "Placebo to risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 499, "start_date": "2020-12-15", "completion_date": "2024-06-21", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 35, "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624243" }, { "nct_id": "NCT03557931", "title": "A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ASP4345", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "ziprasidone", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "brexpiprazole", "type": "DRUG" }, { "name": "paliperidone", "type": "DRUG" }, { "name": "lurasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 233, "start_date": "2018-07-13", "completion_date": "2019-10-21", "has_results": true, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 27, "location_summary": "Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557931" }, { "nct_id": "NCT01770600", "title": "Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Impulsivity", "Active Suicidal Ideation", "Depression" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "Riperidone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 0, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-28", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770600" }, { "nct_id": "NCT04587115", "title": "Reducing the Abuse Liability of Prescription Opioids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Addiction" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2017-06-16", "completion_date": "2020-01-01", "has_results": false, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04587115" }, { "nct_id": "NCT04567524", "title": "A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia Schizoaffective" ], "interventions": [ { "name": "LYN-005", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lyndra Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 34, "start_date": "2020-08-13", "completion_date": "2020-12-22", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 5, "location_summary": "Long Beach, California • Atlanta, Georgia • Marlton, New Jersey + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" }, { "city": "Richardson", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04567524" }, { "nct_id": "NCT03818256", "title": "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antipsychotic-induced Weight Gain (AIWG)" ], "interventions": [ { "name": "Miricorilant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2019-12-04", "completion_date": "2022-07-06", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 27, "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03818256" }, { "nct_id": "NCT00975611", "title": "Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Amantadine Hydrochloride, USP", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David C. Henderson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2009-10", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2013-06-10", "last_synced_at": "2026-10-05T19:28:52.443Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975611" } ] }